top of page

Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis

New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.


Click on this link for more information.


source: http://www.europeanpharmaceuticalreview.com/39447/news/industry-news/cosentyx-superior-skin-clearance-psoriasis/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page